Taxol + TOCOSOL Paclitaxel
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Neoplasm
Conditions
Breast Neoplasm
Trial Timeline
Sep 1, 2005 → Sep 1, 2007
NCT ID
NCT00251095About Taxol + TOCOSOL Paclitaxel
Taxol + TOCOSOL Paclitaxel is a phase 3 stage product being developed by Achieve Life Sciences for Breast Neoplasm. The current trial status is terminated. This product is registered under clinical trial identifier NCT00251095. Target conditions include Breast Neoplasm.
What happened to similar drugs?
20 of 20 similar drugs in Breast Neoplasm were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00251095 | Phase 3 | Terminated |
Competing Products
20 competing products in Breast Neoplasm